OIS Podcast with Elad Kedar, CEO or Orasis Pharmaceuticals

From Ophthalmology Innovation Summit (OIS). Elad Kedar, CEO of Orasis Pharmaceuticals, explains the concept of pupil modulation, the mechanism of action behind Orasis Pharmaceuticals’ candidate drop to treat presbyopia. He reviews Phase IIb trial results and describes the design of the ongoing Phase III trial.

Click here to watch the video.

Shared by Tyler Stowater, board member of Orasis Pharmaceuticals.